BMPARK
NEW THERAPEUTICS FOR PARKINSON'S

A Marie Slodowska-Curie funded research programme

BMPARK is studying the therapeutic potential of Neurotrophic factors in Parkinson's disease.


Parkinson’s disease is a neurodegenerative disorder that affects 1% of people over the age of 65 years. This amounts to 1.2 million people in Europe and this number is expected to double by 2030. The progressive loss of dopamine producing neurons in the midbrain leads to the characteristic motor symptoms of Parkinson's. Unfortunately there are no therapies that stop the progressive loss of these neurons.

Information about Parkinson's disease and the latest BMPARK news will appear here from September 2020 onwards.

 

©2020 by BRAIN DEVELOPMENT AND REPAIR GROUP.